HCV-associated Marginal Zone Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-HCV-MZL |
|---|---|
| Type | Disease |
| Aliases | HCV-MZLHepatitis C virus-associated marginal zone lymphomaГепатит-C-асоційована MZLЛімфома маргінальної зони, асоційована з HCV |
| Status | reviewed 2026-04-24 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MZL-2024 SRC-MOZ-UA-LYMPH-2013 SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9699/3 |
|---|---|
| icd_o_3_topography | [] |
| icd_10 | C88.4 |
| who_classification | B-cell neoplasms — Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) |
Notes
Reference case "Patient Zero" per specs/REFERENCE_CASE_SPECIFICATION.md. Etiological-driven archetype — treatment fundamentally shaped by HCV status (antiviral-first logic).
Used By
Actionability
BMA-HCV-RNA-MONITORING-DAA-RESPONSE- Quantitative HCV RNA monitoring during direct-acting antiviral (DAA) therapy: pretreatmen...BMA-MYD88-L265P-HCV-MZL- MYD88 L265P found in ~5-10% of MZL (more in lymphoplasmacytoid variants; rare in classic...
Algorithms
ALGO-HCV-MZL-1L- ALGO-HCV-MZL-1LALGO-HCV-MZL-2L- ALGO-HCV-MZL-2L
Disease
DIS-NODAL-MZL- Nodal Marginal Zone LymphomaDIS-SPLENIC-MZL- Splenic Marginal Zone Lymphoma
Indication
IND-CHRONIC-HCV-PREVENTION-DAA- IND-CHRONIC-HCV-PREVENTION-DAAIND-CHRONIC-HCV-PREVENTION-OBSERVATION- IND-CHRONIC-HCV-PREVENTION-OBSERVATIONIND-HCV-MZL-1L-ANTIVIRAL- IND-HCV-MZL-1L-ANTIVIRALIND-HCV-MZL-1L-BR-AGGRESSIVE- IND-HCV-MZL-1L-BR-AGGRESSIVEIND-HCV-MZL-POST-DAA-SURVEILLANCE- IND-HCV-MZL-POST-DAA-SURVEILLANCEIND-SJOGREN-MALT-LYMPHOMA-PREVENTION-OBSERVATION- IND-SJOGREN-MALT-LYMPHOMA-PREVENTION-OBSERVATIONIND-SJOGREN-MALT-LYMPHOMA-PREVENTION-SURVEILLANCE- IND-SJOGREN-MALT-LYMPHOMA-PREVENTION-SURVEILLANCE
Questionnaires
QUEST-HCV-MZL-1L- HCV-associated Marginal Zone Lymphoma — first line
Red flag
RF-AGGRESSIVE-HISTOLOGY-TRANSFORMATION- Histologic evidence of transformation to aggressive large B-cell lymphoma (DLBCL) on biop...RF-BULKY-DISEASE- Bulky lymphoma disease: single nodal mass >=7 cm OR mediastinal mass >1/3 thoracic diamet...RF-CHRONIC-HCV-NHL-PREVENTION-OPPORTUNITY- Chronic HCV infection (HCV-RNA detectable / persistent viremia) in an individual without...RF-DECOMP-CIRRHOSIS- Decompensated cirrhosis (Child-Pugh B or C): ascites, encephalopathy, variceal bleeding,...RF-HBV-COINFECTION- Hepatitis B coinfection: HBsAg positive OR anti-HBc total positive (occult HBV risk). HCV...RF-HCV-MZL-FRAILTY-AGE- HCV-associated MZL patient frail or elderly: ECOG ≥3, OR age ≥75 with ≥2 comorbidities, O...RF-SJOGREN-MALT-LYMPHOMA-PREVENTION- Primary Sjögren's syndrome (chronic autoimmune exocrinopathy with characteristic anti-Ro/...
Sources
SRC-AASLD-HBV-2024- AASLD Practice Guideline on the Treatment of Chronic Hepatitis BSRC-AASLD-IDSA-HCV-2023- AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C (living docume...SRC-ARCAINI-2014- The IELSG-19 randomized trial of MALT lymphoma — chlorambucil + rituximab vs each as mono...SRC-BSH-MZL-2024- British Society for Haematology — Marginal Zone Lymphoma GuidelineSRC-EASL-HCV-2023- EASL Clinical Practice Guidelines on Hepatitis C Virus InfectionSRC-ESMO-LYMPHOMA-2025- Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSRC-ESMO-MZL-2024- ESMO Clinical Practice Guideline on Marginal Zone LymphomasSRC-MOZ-UA-LYMPH-2013- Уніфікований клінічний протокол первинної, вторинної (спеціалізованої) медичної допомоги:...SRC-NCCN-BCELL-2025- NCCN Clinical Practice Guidelines in Oncology: B-Cell LymphomasSRC-NIH-AIDS-2024- NIH HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HI...
Supportive Care
SUP-HBV-PROPHYLAXIS- HBV reactivation prophylaxis with entecavir